Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05099445 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT05099445 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 48 participants.
The verdict
NCT05099445, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a multicenter, open-label parallel-group to evaluate single oral doses of INCB000928 in participants with varying level of renal function or impairment.
Interventions
- DRUG INCB000928
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05099445
The ClinicalTrials.gov registry entry for NCT05099445 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB000928 is the first listed.
NCT05099445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05099445 about?
NCT05099445 is a clinical study titled "Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis". This is a multicenter, open-label parallel-group to evaluate single oral doses of INCB000928 in participants with varying level of renal function or impairment.
What is the current status of trial NCT05099445?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2021-12-14. Estimated completion is 2023-02-27.
What interventions are being tested in trial NCT05099445?
The interventions under investigation include: INCB000928 (DRUG).
Who is sponsoring clinical trial NCT05099445?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.